The Exchange has sought clarification from Cipla Limited with respect to recent news item captioned Pharma stocks slump as Trump shoots letters to 17 global drug majors seeking lower prices. The response from the Company is attached.
CIPLA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Cipla Limited responded to a clarification sought by stock exchanges regarding a news article that mentioned pharma stocks slumping after Trump sent letters to 17 global drug majors seeking lower prices. The company clearly stated that it has not received any such communication from the US administration. Cipla also clarified that it is not aware of any undisclosed information that could explain recent movement in its stock price on the exchanges. The clarification was filed on 1st August 2025 by Rajendra Chopra, Company Secretary of Cipla. The company essentially distances itself from the specific news report while not commenting on broader sector pressure.
Short-term: The denial of any direct communication from Trump may provide mild relief to investors worried about company-specific US pricing action. However, the broader sector overhang from US drug pricing pressure remains unresolved and could continue to weigh on pharma stocks including Cipla.